Leading French generic drug company Biogaran continues its development in Africa with the launch of its activities in Gabon
Mrs Audrey Chambrier, Mr Philippe Autier, Mr Max Limoukou and Mr Emmanuel Le Doeuff (from the left to the right) at the launching ceremony in Libreville, Gabon, on November 21st 2019
The pharmaceutical company Biogaran, one of the pioneers of generic drugs in France, has announced the launch of its activities in Gabon. Indeed, Biogaran is now providing patients with 32 drugs from its range of nearly 900 references. On this occasion, an opening conference was held on Thursday, November 21st at the Hotel Méridien Ré-Ndama, in the presence of the Minister of Health, Max Limoukou, of the French Ambassador to Gabon, Philippe Autié, of the Deputy Managing Director of the National Health Insurance and Social Welfare Fund, Audrey Chambrier and of the Managing Director, Head Pharmacist and International Affairs Director, Emmanuel Le Dœuff.
Biogaran, a subsidiary of Servier group specialized in generics, intends to contribute to promote access to quality drugs and to fight against counterfeit drugs in Gabon and Central Africa. Indeed, according to the World Health Organization (WHO), around 100 000 people die every year in Africa from the use of counterfeit drugs. In this context, Biogaran provides patients with quality and bioequivalent drugs that will also have a tamper-proof packaging to ensure their security and effectiveness.
Biogaran drugs cover a wide range of diseases that are increasingly prevalent on the African continent, such as high blood pressure and diabetes, of which Gabon is the third most affected country in the sub-region according to the International Diabetes Federation (IDF). The pharmaceutical company also aims to market 10 new drugs each year to address public health needs in the country.
“Biogaran wishes to promote access to quality drugs in Africa. Gabon benefits from a groundbreaking healthcare system that encourages Biogaran to develop its activities in the country. Beyond the quality of the drugs, Biogaran will provide healthcare professionals and patients with a wide range of services to promote the good use of medicines” declares Emmanuel Le Doeuff, Managing Director, Head Pharmacist and International Affairs Director of Biogaran.
“Biogaran is now an alternative for the availability of generic medicines that meet the most stringent European standards. We are counting on your professionalism to fulfill our demand and to anticipate any difficulties in the supply of pharmaceutical products in our health facilities. We are ready to explore with you all the possibilities required to explore a public-private partnership in the interest and well-being of our populations.”, explains Max Limoukou, Minister of Health.
Moreover, the generic drug company will support Gabonese patients and health professionals in the use of their drugs by implementing a drug safety system with a pharmacist who will collect all cases of pharmacovigilance and medical information.
After the acquisition of Swipha in 2017, a Nigerian generic drug company for the domestic market, and the commercialization of its drugs in Ivory Coast, the Republicof Congo and Gabon, Biogaran plans on launching its activities in Senegal, Mali and Guinea-Conakry in 2020.
Biogaran is a French pharmaceutical laboratory specialized in generic drugs, a subsidiary of Servier and headquartered in Colombes (France). Founded in 1996, it is now the French leader in generic drugs. In 2018, Biogaran generated gross sales of €1.252 billion with 290 million units sold. Internationally, the group is present in Brazil through Pharlab, and in Nigeria with the acquisition of Swipha in 2017, a local generic specialist.
More information: www.biogaran.fr
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
More information: www.servier.com